Trelegy ellipta pack shot with molecules around it
Molecules matter: choose innovation that delivers an uninterrupted 24 hour effect1,13

The only COPD Triple Therapy that delivers an uninterrupted 24 hour effect from a single inhalation1,13

Fluticasone furoate and vilanterol are not licensed as monotherapies in COPD.

*The clinical significance of in vitro data is not known.

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The only triple therapy with evidence of superior component molecules in the following classes:

molecules table

*Analysis based on a subset of patients whose randomisation stratum and pre-randomisation treatment included an ICS and a LABA. Patients could receive a LAMA throughout the treatment period in addition to their randomised treatment.

Relvar Ellipta 92/22mcg is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilation therapy. No double blind, randomised controlled comparative studies versus FP/SAL or versus other established bronchodilators have been conducted to appropriately compare the effects on COPD exacerbations.15

What does this mean for your patients?

Trelegy Ellipta has been intentionally designed to provide your patients with sustained efficacy in the once-daily easy-to-use Ellipta device.1,13,18-20

Prescribing Information Links

Incruse Ellipta prescribing information (PDF)

Relvar Ellipta prescribing information (PDF)

Anoro Ellipta prescribing information (PDF)

Seretide prescribing information (PDF)

Trelegy Ellipta prescribing information (PDF)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.1

Footnotes

ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

References:

  1. Trelegy Ellipta SmPC.
  2. Biggadike K et al. J Med Chem 2008; 51: 3349-3352
  3. Rossios et al. European Journal of Pharmacology 2011 670: 244–251
  4. Boscia et al. Clinical Therapeutics 2012; 34(8): 1655-1666
  5. Biggadike K et al. Clinical Therapeutics 2012; 34(8): 1655-1666
  6. Incruse Ellipta (umeclidinium bromide) SmPC.
  7. Laine DI et al. J Med Chem 2009; 52:2493-2505
  8. Salmon M et al. J of Pharm. & Exp. Ther. 2013; 345:260-270
  9. Feldman G et al. nt J Chron Obstruct Pulmon Dis 2016; 11:719–730.
  10. Slack RJ et al. J Pharmacol Exp Ther 2013; 344:218–230.
  11. Hanania NA; CHEST; 2012;142;119-127
  12. Kempsford et al. Pulm Pharmacol Ther. 2013; 26(2): 256-64
  13. Lipson DA Adv Ther 2020; 37;4894-4909
  14. Vestbo J et al. N Engl J Med 2016; 375:1253-60
  15. Relvar Ellipta SmPC
  16. Maltais F et al. Adv Ther 2019;36:2434-2449
  17. Feldman GJ et al. Adv Ther 2017; 34:2518-2533
  18. Svedsater H et al. BMC Pulm Med 2013; 13:1–14.
  19. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  20. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873– 1880.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with

Innoviva logo

November 2021 | PM-GB-FVU-WCNT-210007 V2.0